Associated Papers
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.
Pecci F et al.
Cancer Discovery, 2024
38564707 (PubMed )
Supplement: cd-23-1217_supplementary_table_5_suppst5.xlsx › table_uff
Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
Roosan MR et al.
Chest, 2021
33878340 (PubMed )
Supplement: mmc1.pdf
Spatially interacting phosphorylation sites and mutations in cancer.
Huang KL et al.
Nature Communications, 2021
33875650 (PubMed )
Supplement: 41467_2021_22481_MOESM4_ESM.xlsx › TableS5.ActMutationClusters
Pan-urologic cancer genomic subtypes that transcend tissue of origin.
Chen F et al.
Nature Communications, 2017
28775315 (PubMed )
Supplement: 41467_2017_289_MOESM7_ESM.xlsx › mutation_data
Whole-Exome Sequencing-Based Mutational Profiling of Hepatitis B Virus-Related Early-Stage Hepatocellular Carcinoma.
Zhan H et al.
Gastroenterology Research and Practice, 2017
29333154 (PubMed )
Supplement: 2029315.f1.pdf
Gastrointestinal malignancies harbor actionable MET exon 14 deletions.
Lee J et al.
Oncotarget, 2015
26375439 (PubMed )
Supplement: oncotarget-06-28211-s003.xlsx › Cosmic_MET
Select a paper to view details